Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 1
2009 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes.
Dashora U, Ashwell SG, Home PD. Dashora U, et al. Diabetes Obes Metab. 2009 Jul;11(7):680-7. doi: 10.1111/j.1463-1326.2008.01024.x. Diabetes Obes Metab. 2009. PMID: 19527481 Clinical Trial.
RESULTS: There was no difference between BIAsp and BHI in geometric weighted average serum glucose over 24 h [7.3 vs. 7.7 mmol/l, BIAsp/BHI ratio 0.95 (95% CI 0.88-1.02), not significant (NS)], but daytime geometric weighted average glucose concentration was significantly …
RESULTS: There was no difference between BIAsp and BHI in geometric weighted average serum glucose over 24 h [7.3 vs. 7.7 mmol/l, BIA …
Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes.
Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, Shutler SD, Stephens JW, Home PD. Ashwell SG, et al. Diabet Med. 2006 Mar;23(3):285-92. doi: 10.1111/j.1464-5491.2005.01781.x. Diabet Med. 2006. PMID: 16492212 Clinical Trial.
This was confirmed by an 8% lower 24-h plasma glucose area under the curve (AUC) (187 vs. 203 mmol l(-1) h(-1), P = 0.037), a 24% reduction in plasma glucose AUC > 7.0 mmol/l1 (47 vs. 62 mmol l(-1) h(-1), P = 0.017) and a 15% lower post-prandial plasma glucose AU …
This was confirmed by an 8% lower 24-h plasma glucose area under the curve (AUC) (187 vs. 203 mmol l(-1) h(-1), P = 0.037), a 24% red …
Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
Dashora UK, Sibal L, Ashwell SG, Home PD. Dashora UK, et al. Diabet Med. 2007 Apr;24(4):344-9. doi: 10.1111/j.1464-5491.2007.02094.x. Epub 2007 Jan 12. Diabet Med. 2007. PMID: 17298589 Clinical Trial.
RESEARCH DESIGN AND METHODS: In this 16-week, double-blind, placebo-controlled study, people with Type 2 diabetes [n = 55, HbA(1c) 8.2 +/- 1.0 (+/- sd)%, duration of diabetes 12.8 +/- 6.0 years, duration of insulin treatment 6.0 +/- 4.0 years] were transferred to single be …
RESEARCH DESIGN AND METHODS: In this 16-week, double-blind, placebo-controlled study, people with Type 2 diabetes [n = 55, HbA(1c) 8. …
Predicting the development of macrovascular disease in people with type 1 diabetes: A 9-year follow-up study.
Sibal L, Law HN, Gebbie J, Dashora UK, Agarwal SC, Home P. Sibal L, et al. Ann N Y Acad Sci. 2006 Nov;1084:191-207. doi: 10.1196/annals.1372.037. Ann N Y Acad Sci. 2006. PMID: 17151302
People who developed macrovascular complications were older (48 +/- 12 versus 36 +/- 11 [SD] years; P = 0.000), had longer duration of diabetes (28 +/- 12 versus 18 +/- 11 years; P = 0.000), higher BMI (26.7 +/- 4.6 versus 25.4 +/- 3.6 kg/m2; P = 0.041), higher base line serum ch …
People who developed macrovascular complications were older (48 +/- 12 versus 36 +/- 11 [SD] years; P = 0.000), had longer duration of diabe …